NCT04353375 - Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

September 3, 2020

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

Advanced Intrahepatic Cholangiocarcinoma

Interventions

DRUG

HMPL-453

Cohort\_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort\_2:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle)

Trial Locations (1)

Unknown

RECRUITING

Chinese PLA General Hospital, Beijing